Know Cancer

or
forgot password

A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma


Phase 3
18 Years
N/A
Not Enrolling
Both
Multiple Myeloma

Thank you

Trial Information

A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma


This is a research study with an experimental drug called siltuximab (also known as CNTO
328). Siltuximab is being developed to see if it may be useful in treating multiple myeloma,
including multiple myeloma that has returned after (relapsed) or did not respond
(refractory) to previous treatment. Multiple myeloma is a type of cancer that affects the
blood and bone marrow. The cancer cells in the bone marrow can cause the normal bone marrow
cells to breakdown. This can result in low levels of red blood cells (which may make the
patient feel tired or fatigued), low levels of white blood cells (which may increase the
patient's chances of infections) or low levels of platelets (which may increase risk of
bleeding). The cancer cells can cause damage to the normal bone. This can cause bone pain,
bone fractures, and can increase the level of calcium in the blood. The cancer cells also
make proteins (called M-proteins), which can result in damage to other organs, especially
the kidneys. Siltuximab is a chimeric (part mouse and part human) antibody (immunoglobulin
that is important for fighting infection). Siltuximab blocks another small protein called
Interleukin 6 (IL-6). The body makes IL-6 naturally, and at normal levels it is important
for the inflammatory response. But high levels of IL-6 can help cancer cells grow and
interfere with chemotherapy drugs killing cancer cells. Cancer-related sicknesses such as
weight loss, bone weakening, and depression have been linked to high levels of IL-6. This
study tests the effectiveness and safety of siltuximab when it is taken together with
Velcade and dexamethasone. There are two treatment groups, Arm A and Arm B. To try to make
sure the groups are similar, patients will be put into Arm A or Arm B, randomly (by chance),
like flipping a coin. Patients in Arm A will receive siltuximab plus Velcade and
dexamethasone. Patients in Arm B will receive placebo plus Velcade and dexamethasone. About
500 patients will participate in the study. Velcade, also known as bortezomib, is injected
directly into the vein all at once. This is called an intravenous (IV) push. Siltuximab or
placebo is given as a 1 hour IV infusion through a small tube that goes directly into the
vein. Dexamethasone is given orally. The treatment period is divided into cycles lasting
about 21 days which will last until the patient's multiple myeloma gets worse, side effects
that are not acceptable happen or when the patient decides to withdraw consent for
treatment, whichever occurs first. Siltuximab 11mg/kg or placebo will be given on Day 1 of
every cycle. Velcade 1.3 mg/m2 will be given on Days 1, 4, 8 and 11 for Cycles 1-8, and on
Days 1 and 8 for Cycles 9 and higher. Dexamethasone 20 mg will be given on the day of and
the day after each Velcade dose. Safety assessments will be performed throughout the study
and include obtaining and evaluating laboratory tests, vital signs (e.g. blood pressure),
and checking the occurrence and severity of adverse events. Disease assessments will also be
performed and include obtaining and evaluating blood and 24 hour urine samples, bone marrow
aspirate and/or biopsy samples and clinical and radiologic evaluations. After treatment,
patients will enter the follow-up period, which includes visits up to 12 weeks after the
last dose and checks every three months until death or the end of the study. Patients who
stop treatment before their multiple myeloma gets worse will have disease assessments until
their disease gets worse, they start a new multiple myeloma treatment, they decide to
withdraw consent for study participation or the end of the study, whichever happens first.
Siltuximab or placebo plus Velcade and dexamethasone will be given in 21-day treatment
cycles until worsening of disease (progression), unacceptable toxicity or withdrawal of
consent for treatment, whichever comes first. Siltuximab 11 mg/kg or placebo will be given
on Day 1 of every cycle. Velcade 1.3 mg/m2 will be given on Days 1, 4, 8 and 11 for Cycles
1-8, and on Days 1 and 8 for Cycles 9 and higher. Dexamethasone 20 mg will be given on the
day of and the day after each Velcade dose.


Inclusion Criteria:



- Confirmed diagnosis of multiple myeloma requiring treatment

- Measurable secretory disease, defined as either serum M-protein >=1 g/dL or urine
M-protein (light chain) >=┬┐200 mg/24 hours

- Must have received 1 to 3 lines of prior treatment for multiple myeloma

- Must have achieved a response (Minimal Response or better) to at least 1 prior line
of treatment

- Must have progressed on or been refractory (defined as < Minimal Response or disease
progression within 60 days of last dose) to the most recent line of treatment

- Must not be refractory to any previous line of treatment that included a proteasome
inhibitor

- Qualifying hematology and chemistry laboratory results.

Exclusion Criteria:

- Diagnosis of primary amyloidosis, plasma cell leukemia, or other conditions in which
a paraprotein is present in the absence of a clonal plasma cell infiltration with
lytic bone lesions

- Grade 1 peripheral neuropathy with pain or Grade 2 or higher peripheral neuropathy

- Allogeneic bone marrow transplantation within 28 days

- Bone marrow transplant planned within 12 months after study start

- Chemotherapy or radiation therapy within 21 days

- Clinically significant infection, including known HIV or hepatitis C infection, or
known hepatitis B surface antigen positivity

- Major surgery within 21 days before or planned during the study

- Subjects who the investigator believes would not tolerate starting doses of VELCADE
or dexamethasone

- Significant cardiac disease or myocardial infarction within 6 months

- Vaccination with live attenuated vaccines within 4 weeks

- Prior exposure to agents targeting IL-6 or the IL-6 receptor

- Received any investigational agent within 30 days┬┐

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

Progression-free survival (PFS)

Outcome Time Frame:

Event driven, i.e. every 3-4 weeks until progression, death, or end of study (5 years after first patient is dosed)

Safety Issue:

No

Principal Investigator

Centocor, Inc. Clinical Trial

Investigator Role:

Study Director

Investigator Affiliation:

Centocor, Inc.

Authority:

United States: Food and Drug Administration

Study ID:

CR017743

NCT ID:

NCT01266811

Start Date:

July 2011

Completion Date:

December 2014

Related Keywords:

  • Multiple Myeloma
  • dexamethasone
  • Siltuximab
  • CNTO 328
  • IL-6
  • Monoclonal Antibody
  • Multiple Myeloma
  • Relapsed or Refractory
  • Velcade
  • bortezomib
  • Multiple Myeloma
  • Neoplasms, Plasma Cell

Name

Location

Bettendorf, Iowa  52722
Cleveland, Ohio  44195
Philadelphia, Pennsylvania  19104
Boston, Massachusetts  
Milwaukee, Wisconsin